Work

Op0164 Bliss-ln: a Randomised, Double-blind, Placebo-controlled Phase 3 Trial of Intravenous Belimumab in Patients With Active Lupus Nephritis

Year: 2020

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2020-eular.3881

Authors: R. Furie, B.H. Rovin, F. Houssiau, Z. Amoura, M. Santiago, G. Contreras, A. Malvar, C.C. Mok, A. Saxena, X. Yu, Y.K.O. Teng, C. Barnett, S. Burriss, Y. Green, B. Ji, C. Kleoudis, D. Roth

Institutions: Northwell Health, The Ohio State University, Cliniques Universitaires Saint-Luc, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Escola Bahiana de Medicina e Saúde Pública, University of Miami, Tuen Mun Hospital, New York University, The First Affiliated Hospital, Sun Yat-sen University, Leiden University Medical Center, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), PAREXEL International (United States)

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, Insmed, InflaRx, Genentech, Chugai Pharmaceutical

OpenAlex ID: W3038221340

Cites:

Cited by: 14

Related to: 10